tirzepatide comparison
Retrieved from Karamanolis, G., Theofanidou, I., Yiasemidou, M., Giannoulis, E., Triantafyllou, K., & Ladas, S
Compounding and the FDA: Questions and answers, Food and Drug Administration (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2024) Mounjaro, DailyMed (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
GLP-1 receptor agonists such as semaglutide and dulaglutide work by enhancing insulin secretion and promoting satiety, whilst SGLT2 inhibitors like dapagliflozin and empagliflozin promote urinary glucose excretion